systemic%20lupus%20erythematosus%20(pediatric)
SYSTEMIC LUPUS ERYTHEMATOSUS (PEDIATRIC)
Systemic lupus erythematosus is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
It can be suspected when ≥2 organ systems are involved.
It is predominantly diagnosed in females of childbearing age, rarely diagnosed before 8 years old.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Majority of patients have arthralgia of the hand.
Drug Information

Indication: Psoriasis (excluding widespread plaque psoriasis), recalcitrant eczemas, lichen planus, discoid lupus erythema...

Indication: Eczema including atopic, infantile, discoid & stasis eczema; prurigo; psoriasis; neurodermatoses including...

Indication: Short-term treatment of corticosteroid-responsive resistant dermatoses eg, psoriasis, recalcitrant eczema, lic...

Indication: Symptomatic treatment of allergic dermatoses & other forms of contact dermatitis, insect bites; atopic, ec...

Indication: Reducing disease activity in adult patients w/ active autoantibody +ve SLE receiving standard therapy.

Indication: Relief of inflammatory manifestations of corticosteroid-responsive dermatoses.

Indication: Suppression of skin diseases in which inflammation is a prominent feature.

Indication: Suppression of skin diseases in which inflammation is a prominent feature.

Indication: Relief of inflammatory & pruritic manifestations of corticosteroid-responsive dermatoses (eg, psoriasis, e...

Indication: Acute & chronic rheumatic fever, RA, bronchial asthma, myositis, dermatitis.

1  /  6
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2019
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
2 days ago
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 13 Jun 2019

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

13 Jun 2019
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.